Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cefazolin + tobramycin + gentamicin
- Development stage
- Preclinical
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Ophthalmic, Intravenous, Intramuscular
01
Overview
A combination of three antibiotics including cefazolin (a first-generation cephalosporin) and two aminoglycosides (tobramycin and gentamicin). This combination is not a standard commercial formulation but may be used in specific clinical scenarios where broad-spectrum coverage is needed. Cefazolin inhibits bacterial cell wall synthesis, while aminoglycosides like tobramycin and gentamicin work by binding to bacterial ribosomes and inhibiting protein synthesis. The combination may provide synergistic bactericidal activity against certain bacterial strains.
02
Targets
Bacterial Ribosome16S rRNA (16S ribosomal RNA)PBP (Penicillin-binding protein family)Neuraminidase
Beyond the preview
Go deeper on cefazolin + tobramycin + gentamicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cefazolin + tobramycin + gentamicin.